Continuous Bioprocessing Market

Semi-Continuous and Continuous Bioprocessing Market by Type of Manufacturer, Company Size, Scale of Operation, Stage of Bioprocess, Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    146

  • Pages
    191

  • View Count
    11688

Continuous and Semi-Continuous Bioprocessing Market

The semi-continuous and continuous bioprocessing market is estimated to be worth $310 million in 2021 and is expected to grow at CAGR of 8.4% during the forecast period. For years, the batch and fed-batch processing technique has been the only available solution for biomanufacturing. However, this method is plagued with several shortcomings, such as process inefficiencies, high risk of human errors and low production speeds. Modern biopharmaceuticals demand faster, and more efficient technologies, preferably with seamless transition into succeeding steps; the primary goal, in this regard, being the preservation of sterility. In other words, a continuous bioprocessing approach is better suited to the needs of the aseptic manufacturing paradigm that is required for biologics. In this context, the introduction of perfusion bioreactors in the late 1980s was a revolutionary development within the industry. Presently, there are multiple available technologies that are capable of supporting continuous downstream (including clarification / centrifugation, filtration, and chromatography steps) and upstream bioprocesses (which include cell line development and other pre-fermentation steps). A significant number of biopharmaceutical companies, especially certain big pharma players and large contract manufacturing service providers, claim to have already adopted, or are considering installing, continuous bioprocessing technologies, such as perfusion bioreactors, continuous chromatography and continuous filtration equipment. Continuous flow systems have been proven to address a number of challenges associated with traditional bioprocessing; for instance, they facilitate the lowering of manufacturing costs (by 60%), reduction in buffer use (by 30-50%), optimization of resin consumption (by 70%) in chromatography columns, reduction in product change over time (by 90%), improvement of product consistency across different batches (by 50%), minimizing facility footprints (by 50-70%), reduction in operating expenditure (by 90%) and seamless scale up. All the aforementioned advantages eventually serve to improve overall productivity.

The current focus of the users of this novel technology is primarily on upgrading individual operations to the continuous mode; as indicated earlier, some companies have already established bioprocessing lines with multiple continuous processes. Cost, (end product) quality, processing speed and operational flexibility are some of the primary driving factors of the gradual shift to continuous bioprocessing. The COVID-19 pandemic has also contributed to accelerating the adoption of continuous flow systems. Some of the existing challenges in this field include complexities related to defining continuous processes (especially those upstream to the fermentation step), and aligning the available equipment to operate as per current GMP requirements. Although an end-to-end continuous bioproduction line is still several years away, we believe that the opportunity for both innovators and service providers engaged in this domain is likely to grow in the foreseen future.

Continuous-Bioprocessing-Market-Context-Roots-Analysis-thumb Continuous-Bioprocessing-Market-List-of-Companies-Roots-Analysis-thumb Continuous-Bioprocessing-Market-Distribution-by-Scale-of-Operation-Roots-Analysis-thumb

Key Companies in Semi-Continuous and Continuous Bioprocessing Market

Examples of key companies engaged in semi-continuous and continuous bioprocessing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Biogen, Bristol-Myers Squibb, Sanofi Genzyme, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Novasep, UCB Pharma, Enzene Biosciences and WuXi Biologics. This market report includes an easily searchable excel database of all the companies using semi-continuous and continuous bioprocessing for manufacturing, worldwide.

Recent Developments in Continuous and Semi Continuous Market:

Several recent developments have taken place in the field of continuous and semi continuous. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In April 2023, Arranta Bio (a Recipharm firm) entered into an agreement with MIT to develop a continuous manufacturing technology for mRNA therapeutics.  
  • In April 2023, Exothera inked a deal with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA.
  • In March 2023, Curia collaborated with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system to support higher-quality API-chemical production using flow-chemistry technology.

Scope of the Report

The “Continuous and Semi-Continuous Bioprocessing Market by Type of Manufacturer (Innovator / Drug Developer and Contract Service Provider), Company Size (Large, Mid-Sized and Small), Scale of Operation (Preclinical / Clinical and Commercial), Stage of Bioprocess (Upstream and Downstream), Geographical Regions (North America, Europe and Asia Pacific): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study on the companies having continuous and semi-continuous bioprocessing capabilities. The study underlines an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

	Continuous-Bioprocessing-Market-Geographical-Distribution-by-Location-Roots-Analysis-thumb Continuous-Bioprocessing-Market-Drug-Developers-Roots-Analysis-thumb Continuous-Bioprocessing-Market-Equipment-Providers-Roots-Analysis-thumb

Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the companies that have adopted continuous and semi-continuous bioprocessing, including analyses based on a number of relevant parameters, such as year of establishment, company size, type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters, locations of continuous and semi-continuous bioprocessing facilities of innovators, locations of continuous and semi-continuous bioprocessing facilities of contract service providers, type of facility (modular and conventional), type of bioreactor (single-use and stainless steel), stage of bioprocess (upstream and downstream), primary continuous and semi-continuous bioprocessing (continuous cell culture, continuous clarification / harvesting, continuous purification, process analytical technology and others), secondary continuous and semi-continuous bioprocessing (N-1 stage perfusion, N stage perfusion, continuous concentrated fed-batch, continuous cell retention, continuous centrifugation, continuous chromatography and continuous viral filtration), types of biologics manufactured (antibodies, proteins / peptides, vectors, enzymes and others) and details on the continuous and semi-continuous production capacity.
  • Tabulated profiles of the key players offering a wide range of services for the continuous and semi-continuous bioprocessing of products across North America, Europe and Asia-Pacific. Each profile features a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing related capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.
  • Key initiatives taken by the leading pharmaceutical companies, taking into consideration both partnered as well as in-house projects.
  • A case study to depict the overall landscape of the continuous and semi-continuous bioprocessing equipment providers, based on a number of parameters, such as type of equipment, type of manufacturing process (continuous and batch-continuous), stage of bioprocess (upstream process and downstream process) and scale of operation (preclinical / clinical and commercial).
  • An insightful analysis highlighting the cost saving potential associated with the adoption of continuous and semi-continuous bioprocessing technologies.
  • A detailed analysis to estimate the global, continuous upstream bioprocessing capacity based on the capacities of various industry stakeholders. The study includes the distribution of capacity, based on company size (small, mid-sized and large), type of manufacturer (innovator / drug developer and contract service provider), scale of operation (preclinical, clinical and commercial), location of headquarters (North America, Europe and Asia-Pacific) and location  of continuous and semi-continuous bioprocessing facilities (North America, Europe and Asia-Pacific).

One of the key objectives of the report was to estimate the current market size and the growth opportunities in the continuous and semi-continuous bioprocessing market, over the next decade. Based on different parameters, such as global biopharmaceutical market, cost of goods sold, manufacturing cost of biologics, share of API manufacturing, upstream and downstream costs in biologics manufacturing, we have provided informed estimates on the evolution of the market for the period 2021-2030. In order to provide a detailed future outlook, year-wise projections of the current and forecasted opportunity have been further segmented across [A] type of manufacturer (innovator / drug developer and contract service provider), [B] company size (large, mid-sized and small), [C], scale of operation (preclinical / clinical and commercial), [D] stage of bioprocess (upstream and downstream), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

Continuous-Bioprocessing-Market-Likely-Cost-Saving-Potential-Roots-Analysis-thumb Continuous-Bioprocessing-Market-Capacity-Analysis-Roots-Analysis-thumb Continuous-Bioprocessing-Market-Forecast-Roots-Analysis-thumb

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The perceptions presented in this study were also influenced by discussions held with senior stakeholders in this industry. The report features detailed transcripts of interviews held with the following individuals:

  • Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)
  • Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
  • Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is bioprocessing?

Answer: Bioprocessing refers to a complex controlled process of using complete cellular cultures to obtain the desired small molecules, metabolites or cellular extracts.

Question 2: How big is the semi-continuous and continuous bioprocessing market?

Answer: The semi-continuous and continuous bioprocessing market size is estimated to be worth $310 million in 2021.

Question 3: What is the projected market growth of the semi-continuous and continuous bioprocessing market?

Answer: The semi-continuous and continuous bioprocessing market is expected to grow at compounded annual growth rate (CAGR) of 8.4% during the forecast period 2021 – 2030.

Question 4: Who are the leading companies in the semi-continuous and continuous bioprocessing market?

Answer: Examples of key companies engaged in semi-continuous and continuous bioprocessing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AGC Biologics, Biogen, Bristol-Myers Squibb, Sanofi Genzyme, FUJIFILM Diosynth Biotechnologies, Merck KGaA, Novasep, UCB Pharma, Enzene Biosciences and WuXi Biologics.

Question 5: How many companies are currently engaged in the semi-continuous and continuous bioprocessing market?

Answer: Over 70 companies are currently engaged in the semi-continuous and continuous bioprocessing market.

Question 6: What is the cost reduction potential in opting continuous bioprocessing?

Answer: Use of continuous bioprocessing can save up to 60% in the overall cost of production of small molecules.

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com